These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30171698)

  • 21. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
    Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
    J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(®) lamp.
    Reinhold U; Dirschka T; Ostendorf R; Aschoff R; Berking C; Philipp-Dormston WG; Hahn S; Lau K; Jäger A; Schmitz B; Lübbert H; Szeimies RM
    Br J Dermatol; 2016 Oct; 175(4):696-705. PubMed ID: 26921093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ingenol mebutate gel for actinic keratosis.
    Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
    N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A seamless phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp.
    Weiss J; Ulrich M; Bukhalo M; Østerdal ML; Bang B; Hanke CW
    Br J Dermatol; 2017 Jun; 176(6):1456-1464. PubMed ID: 28078678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
    Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
    J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences.
    Mark KE; Spruance S; Kinghorn GR; Sacks SL; Slade HB; Meng TC; Selke S; Magaret A; Wald A
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5016-23. PubMed ID: 24709264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A
    Ortner VK; Johansen B; Kilov K; Castillo Mondragón A; Duvold T; Kihl J; Ashcroft FJ; Feuerherm AJ; Pind Laugesen C; Marcker Espersen ML; Manole I; Isberg AP; Andersen AD; Rakvaag E; Zibert JR; Haedersdal M
    BMJ Open; 2022 Oct; 12(10):e061012. PubMed ID: 36198452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    Br J Dermatol; 2007 Dec; 157(6):1132-47. PubMed ID: 17944981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photodynamic therapy using intense pulsed light for treating actinic keratoses and photoaged skin of the dorsal hands: a randomized placebo-controlled study.
    Kohl E; Popp C; Zeman F; Unger P; Koller M; Landthaler M; Karrer S; Szeimies RM
    Br J Dermatol; 2017 Feb; 176(2):352-362. PubMed ID: 27518833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses.
    Zeichner JA; Stern DW; Uliasz A; Itenberg S; Lebwohl M
    J Am Acad Dermatol; 2009 Jan; 60(1):59-62. PubMed ID: 18937999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms.
    Harrison LI; Skinner SL; Marbury TC; Owens ML; Kurup S; McKane S; Greene RJ
    Arch Dermatol Res; 2004 Jun; 296(1):6-11. PubMed ID: 15083310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of Actinic Keratoses Using Topical DNA Repair Enzymes: A Randomized Placebo-Controlled Trial.
    Stoddard M; Herrmann J; Moy L; Moy R
    J Drugs Dermatol; 2017 Oct; 16(10):1030-1034. PubMed ID: 29036257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.
    Stockfleth E; Harwood CA; Serra-Guillén C; Larsson T; Østerdal ML; Skov T
    Br J Dermatol; 2018 Feb; 178(2):433-442. PubMed ID: 29030864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
    Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head.
    Alomar A; Bichel J; McRae S
    Br J Dermatol; 2007 Jul; 157(1):133-41. PubMed ID: 17501955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
    Lebwohl M; Dinehart S; Whiting D; Lee PK; Tawfik N; Jorizzo J; Lee JH; Fox TL
    J Am Acad Dermatol; 2004 May; 50(5):714-21. PubMed ID: 15097955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250 cm
    Bourcier M; Stein Gold L; Guenther L; Andreassen CM; Selmer J; Goldenberg G
    J Dermatolog Treat; 2017 Nov; 28(7):652-658. PubMed ID: 28264612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.
    Lee PK; Harwell WB; Loven KH; Phillips TJ; Whiting DA; Andres KL; Lee JH
    Dermatol Surg; 2005 Jun; 31(6):659-64. PubMed ID: 15996416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resiquimod, a topical drug for viral skin lesions and skin cancer.
    Meyer T; Surber C; French LE; Stockfleth E
    Expert Opin Investig Drugs; 2013 Jan; 22(1):149-59. PubMed ID: 23205468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.